Alchemia announces appointment of Santo Costa as chairman
Australia-based biotech company Alchemia (ASX:ACL) has announced the appointment of Santo Costa as non-executive chairman of the Board of Directors, effective March 1.
Mr Costa (pictured) brings to Alchemia international experience serving in senior leadership roles across the life sciences industry. Over a 30 year period, Mr Costa has held top executive positions including President and Chief Operating Officer of Quintiles Transnational and Senior Vice President, Administration and General Counsel of Glaxo, where he was on the company’s Board of Directors and Executive Committee.
Nathan Drona, who has served as Alchemia’s chairman since July 15, 2013, will remain on the board as a non-executive director.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze